Restructuring and cost reductionsnegative · 3 filings
“The increase was primarily attributable to higher personnel-related expenses, including salaries, severance payments, employee benefits, bonuses, and travel costs.”10-Q · May 13, 2026 ↗
OSR Health, Inc.
OSRH
Market read
OSR Health, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 37 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 7 directly disclosed connections are confirming.
Company+131.2% todayVolume comparison unavailable
Market group0 of 37 activeHealthcare REITs & Services · unavailable
Disclosed network0 of 7 confirmingNo filing-linked name is confirming now
What would change this read
Watch this read- OSRH's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if OSRH's group or a disclosed connection begins moving with it.
Research brief
The story so far
No new filing conclusion is available. 0 of 37 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 7 directly disclosed connections are confirming.
Evidence that supports
No thresholded supportive filing evidence is available yet.
Evidence that challenges
No thresholded adverse filing evidence is available yet.
What would clarify the read
- OSRH's market-adjusted activity becomes unusual and at least one connected name confirms.
Company research
Understand the business, not just the ticker
Business model and earnings drivers
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
Key research questions
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
Annual periods2
Price observations332
Usable filing statements35
Verified relationships7
Evidence supporting the case
No qualifying supportive evidence was identified.
Evidence challenging the case
- Latest annual revenue changed -17.7% year over year.
- Operating margin changed -299.8 percentage points in the latest annual period.
- Restructuring and cost reductions has repeated adverse evidence across 3 filings.
Questions before a position
- EV/sales is 99% below the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context
Price as of Sep 29, 2026
0.126m-73.0%12m-84.1%24m—
Annual trajectory
Reported annual revenue and per-share history. This is accounting history, not a forecast.
PeriodRevenueYoYDiluted EPSShare change
2024-12-31$3.5M—$-4.79—
2025-12-31$2.9M-17.7%$-0.80—
What management says matters
Persistent and emerging business drivers
Foreign exchangenegative · 1 filings
“Industry Context and Market Opportunity The Korean medical device import and distribution sector is under material structural stress, driven by two converging dynamics: ● Foreign exchange pressure: Import purchase obligations are predominantly USD-denominated…”10-K · Mar 31, 2026 ↗
Legal and regulatory exposurepositive · 1 filings
“We incur increased costs as a result of operating as a public company, and our management will devote substantial time to compliance with its public company responsibilities and corporate governance practices.”10-K · Mar 31, 2026 ↗
Macroeconomic conditionsmixed · 1 filings
“In addition, the price of the Company securities can vary due to general economic conditions and forecasts, its general business condition and the release of its financial reports.”10-K · Mar 31, 2026 ↗
Valuation discipline
Descriptive valuation snapshot
Price/sales 0.9× · EV/sales 0.3×. Comparisons use only industry-matched filing peers.
Scenario scaffold
Fewer than 4 annual revenue periods; too little history to scaffold scenarios.
Price action
How the market is pricing the story
0.27+131.2% today
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 30 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for OSRH. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for OSRH. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind OSRH
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
MDTMedtronic plcpartnerMar 31, 2026 ▾
“Drug Name Company Mechanism Indication Infuse Bone Graft Medtronic rhBMP-2 and collagen sponge Spinal fusion, long bone fractures, orthopedic surgery Osteocel Plus NuVasive Demineralized bone matrix (DBM) and mesenchymal stem cells (MSC) Spinal fusion, bone d…”
PENPenumbra, Inc.distributorMar 31, 2026 ▾
“32 Since 2015, RMC has also distributed neuro-intervention medical device equipment manufactured by Penumbra Inc.”
SYKStryker CorporationpartnerMar 31, 2026 ▾
“Drug Name Company Mechanism Indication Infuse Bone Graft Medtronic rhBMP-2 and collagen sponge Spinal fusion, long bone fractures, orthopedic surgery Osteocel Plus NuVasive Demineralized bone matrix (DBM) and mesenchymal stem cells (MSC) Spinal fusion, bone d…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 4 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
OSRH is currently a Follower in the organic co-movement group Healthcare REITs & Services. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for OSRH; it is not active in the latest market snapshot.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.